Showing results (1-10 of 38) with videos related to
Sort By:
Pageof 4
Research and Practice in Thrombosis and Haemostasis|November 2, 2020
Second-line treatments and outcomes for immune thrombocytopenia: A retrospective study with electronic health recordsLincy S Lal, Qayyim Said, Katherine Andrade, et al.Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|December 14, 2017
DPP-4 Inhibitor-Induced Rheumatoid Arthritis Among Diabetics: A Nested Case-Control StudyNiranjan Kathe, Anuj Shah, Qayyim Said, et al.Journal of Medical Economics|November 6, 2019
Healthcare resource use and direct costs in severe aplastic anemia (SAA) patients before and after treatment with eltrombopagBeilei Cai, Qayyim Said, Xin Li, et al.Journal of Medical Economics|July 13, 2019
Healthcare costs and resource utilization in patients with severe aplastic anemia in the USBeilei Cai, Qayyim Said, Xin Li, et al.Journal of Occupational and Environmental Medicine|April 12, 2007
An employer-based cost-benefit analysis of a novel pharmacotherapy agent for smoking cessationKenneth C Jackson, Robert Nahoopii, Qayyim Said, et al.Hypertension Research : Official Journal of the Japanese Society of Hypertension|May 9, 2014
Metabolic syndrome is associated with visit-to-visit systolic blood pressure variability in the US adultsMohammed F Faramawi, Robert Delongchamp, Qayyim Said, et al.Current Medical Research and Opinion|December 15, 2018
Everolimus compliance and persistence among tuberous sclerosis complex patients with renal angiomyolipoma or subependymal giant cell astrocytomaXue Song, Qayyim Said, Oth Tran, et al.Journal of Pain & Palliative Care Pharmacotherapy|November 23, 2007
Problems in studying the association between race and pain in outcomes researchJoanne Lafleur, Qayyim Said, Carrie McAdam-Marx, et al.Clinical Therapeutics|March 23, 2020
The Cost-effectiveness of Eltrombopag for the Treatment of Immune Thrombocytopenia in the United StatesGabriel Tremblay, Mike Dolph, Anuja Nidumolu Roy, et al.Clinicoeconomics and Outcomes Research : CEOR|November 23, 2018
Cost-consequence model comparing eltrombopag versus romiplostim for adult patients with chronic immune thrombocytopeniaGabriel Tremblay, Mike Dolph, Menaka Bhor, et al.Pageof 4